humans |
37 |
animals |
27 |
male |
26 |
propofol |
25 |
analgesia |
23 |
diabetes |
22 |
female |
22 |
oxidative stress |
21 |
adiponectin |
19 |
mortality |
18 |
pain |
18 |
aging |
17 |
biology |
17 |
inflammation |
17 |
obesity |
17 |
adult learning principles |
16 |
collaborative practice |
16 |
evaluation |
16 |
interprofessional education |
16 |
rats |
16 |
cardiovascular disease |
15 |
endothelial cells |
15 |
nitric oxide |
15 |
pharmacy and pharmacology environmental studies |
15 |
toxicology and environmental safety |
15 |
dexmedetomidine |
14 |
endothelium |
14 |
older adults |
14 |
adult |
13 |
aged |
13 |
anaesthesia |
13 |
cirrhosis |
13 |
covid-19 |
13 |
medical sciences |
13 |
mice |
13 |
built environment |
12 |
endothelial dysfunction |
12 |
endothelial function |
12 |
exercise |
12 |
morbidity |
12 |
reactive oxygen species |
12 |
remifentanil |
12 |
adipose tissue |
11 |
animal experiment |
11 |
antioxidants |
11 |
diabetic cardiomyopathy |
11 |
dose-response relationship, drug |
11 |
hypertension |
11 |
middle aged |
11 |
myocardial ischemia injury |
11 |
opioid |
11 |
ablation |
10 |
apoptosis |
10 |
atherosclerosis |
10 |
bridging therapy |
10 |
cardiovascular diseases |
10 |
cells, cultured |
10 |
contraction |
10 |
endothelin-1 |
10 |
endothelium-derived contracting factor |
10 |
enos |
10 |
hepatocellular carcinoma |
10 |
high-intensity focused ultrasound |
10 |
liver transplant |
10 |
mice, inbred c57bl |
10 |
new technology |
10 |
sevoflurane |
10 |
aerosol |
9 |
ampk |
9 |
blood–brain barrier |
9 |
cognition |
9 |
community health |
9 |
cyclooxygenase |
9 |
disease models, animal |
9 |
endothelial nitric oxide synthase |
9 |
general anaesthesia |
9 |
general anesthesia |
9 |
hcc |
9 |
hifu |
9 |
liver cancer |
9 |
local accessibility |
9 |
non-invasive treatment |
9 |
postoperative |
9 |
protein kinase cβ |
9 |
rats, sprague-dawley |
9 |
signal transduction |
9 |
sirt1 |
9 |
survival |
9 |
vascular smooth muscle |
9 |
a-fabp |
8 |
adipokine |
8 |
bradykinin |
8 |
endothelium-dependent contractions |
8 |
endothelium-derived contracting factors |
8 |
fgf21 |
8 |
heme oxygenase-1 |
8 |
hong kong |
8 |
ischemic stroke |
8 |
jak2/stat3 |
8 |
lipocalin-2 |
8 |
mental health |
8 |
neuroinflammation |
8 |
neuropathic pain |
8 |
nitric oxide - metabolism |
8 |
pain management |
8 |
patch-clamp techniques |
8 |
pi3k/akt |
8 |
reactive oxygen species - metabolism |
8 |
relaxation |
8 |
surgery |
8 |
age-friendliness |
7 |
asia |
7 |
blood pressure - drug effects |
7 |
cell line |
7 |
chronic pain |
7 |
cognitive functioning |
7 |
depressive symptoms |
7 |
electrophysiology |
7 |
endothelium, vascular - drug effects - metabolism - physiology |
7 |
endothelium, vascular - drug effects - metabolism - physiopathology |
7 |
functional abilities |
7 |
functional ability |
7 |
health economic analysis |
7 |
health outcomes |
7 |
healthy aging |
7 |
heart |
7 |
hemodynamics - drug effects |
7 |
hypothermia |
7 |
hypoxia |
7 |
imaging |
7 |
intranasal |
7 |
ischaemic stroke |
7 |
jnk/c-jun signalling |
7 |
laparoscopic liver resection |
7 |
living environments |
7 |
long-term outcome |
7 |
longitudinal study |
7 |
macrophages |
7 |
mmp-9 |
7 |
morphine consumption |
7 |
neighbourhood physical environments |
7 |
placebo |
7 |
postoperative pain |
7 |
proliferation |
7 |
prostacyclin |
7 |
public open space |
7 |
rct |
7 |
soluble guanylyl cyclase |
7 |
survival analysis |
7 |
terrain slope |
7 |
time factors |
7 |
vasoconstriction |
7 |
vasoconstriction - drug effects |
7 |
adenosine |
6 |
adipokines |
6 |
anesthetics, inhalation - pharmacology |
6 |
anesthetics, intravenous - pharmacology |
6 |
antioxidants - therapeutic use |
6 |
aorta |
6 |
biogenesis |
6 |
blood coagulation |
6 |
cell density |
6 |
coagulation |
6 |
complications |
6 |
diabetes mellitus |
6 |
elisa |
6 |
empathy |
6 |
endothelial senescence |
6 |
endothelium, vascular - physiology |
6 |
endothelium-derived hyperpolarizing factor |
6 |
enzyme inhibitors - pharmacology |
6 |
ep4 |
6 |
film |
6 |
genistein |
6 |
heart rate - drug effects |
6 |
hypercholesterolemia |
6 |
intraoperative care |
6 |
ischemia reperfusion injury |
6 |
isoproterenol |
6 |
lipocalin |
6 |
lkb1 |
6 |
medical humanities |
6 |
muscle relaxation - drug effects |
6 |
muscle, smooth, vascular - drug effects - metabolism |
6 |
myocardial ischaemia/reperfusion |
6 |
opioids |
6 |
osteoporosis |
6 |
pain - drug therapy |
6 |
perioperative |
6 |
perioperative management |
6 |
prevalence |
6 |
rat |
6 |
rats, inbred shr |
6 |
rats, inbred wky |
6 |
reflective thinking |
6 |
spinal cord stimulation |
6 |
supraglottic airway device |
6 |
tp receptors |
6 |
vasodilatation |
6 |
17β-estradiol |
5 |
acetylcholine - pharmacology |
5 |
acetylcysteine - pharmacology - therapeutic use |
5 |
acute |
5 |
acute kidney injury |
5 |
acute postoperative pain |
5 |
adaptor proteins, signal transducing - antagonists and inhibitors - genetics - physiology |
5 |
adaptor proteins, signal transducing - metabolism |
5 |
adenine - analogs and derivatives - metabolism - pharmacology |
5 |
adipocyte fatty-acid-binding protein |
5 |
adiponectin - biosynthesis - metabolism |
5 |
adiponectin - deficiency - therapeutic use |
5 |
adiponectin - metabolism |
5 |
adolescent |
5 |
aerosol box |
5 |
affinity chromatography |
5 |
aganglionic megacolon |
5 |
aging - metabolism |
5 |
allopurinol - pharmacology - therapeutic use |
5 |
amp-activated protein kinases - metabolism |
5 |
anaesthesiology |
5 |
analgesia, patient-controlled |
5 |
antineoplastic activity |
5 |
antioxidants - pharmacology - therapeutic use |
5 |
aorta, thoracic - drug effects - metabolism - physiopathology |
5 |
aspirin |
5 |
astrocytes |
5 |
autoimmune hypoglycaemia |
5 |
bile acids |
5 |
bilirubin |
5 |
binding, competitive |
5 |
bioaccumulation |
5 |
biomarker |
5 |
biotin |
5 |
blood loss |
5 |
breast cancer |
5 |
calcium |
5 |
camp |
5 |
cancer |
5 |
cardiac dysfunction |
5 |
cardio-renal metabolic syndrome |
5 |
cardiology - education |
5 |
cardiovascular diseases - metabolism - physiopathology |
5 |
carrier proteins - metabolism |
5 |
cell aging - drug effects - physiology |
5 |
cell cycle proteins - metabolism |
5 |
chemicals and cas registry numbers |
5 |
child |
5 |
cholesterol homeostasis |
5 |
ciclosporin |
5 |
coronary vessels - anatomy and histology - drug effects - metabolism |
5 |
cyp2c9 |
5 |
cyp7a1 |
5 |
cytochrome 3a4 |
5 |
dental |
5 |
descriptive epidemiology |
5 |
dexmedetomidine - administration and dosage |
5 |
diabetes complications - drug therapy - metabolism - pathology - physiopathology |
5 |
diabetes mellitus, type 2 - enzymology |
5 |
diagnosis |
5 |
double-blind method |
5 |
education, medical, undergraduate |
5 |
endothelial cells - drug effects - metabolism - physiology |
5 |
endothelial nitric oxide synthase/nitric oxide (enos/no) pathway |
5 |
endothelial regeneration |
5 |
endothelin-1 - metabolism |
5 |
endothelium, vascular - drug effects - physiopathology |
5 |
endothelium, vascular - metabolism |
5 |
endothelium-dependent hyperpolarization |
5 |
escherichia coli - genetics |
5 |
fatty acid-binding proteins - physiology |
5 |
fbxo9 |
5 |
gender |
5 |
gene knockdown techniques |
5 |
genistein - metabolism - pharmacology |
5 |
gluconeogenesis |
5 |
glucose - biosynthesis - metabolism |
5 |
glycogen synthase kinase |
5 |
heart failure |
5 |
hemostatics - therapeutic use |
5 |
hepatocytes - enzymology |
5 |
herb-drug interaction |
5 |
herbal teas |
5 |
hip fractures - surgery |
5 |
histamine |
5 |
hscr |
5 |
humdisease |
5 |
hyperalgesia |
5 |
hyperglycemia |
5 |
hypertriglyceridemia |
5 |
infant |
5 |
infarct size |
5 |
infection |
5 |
inflammation - immunology - metabolism |
5 |
inflammatory pain |
5 |
insulin - metabolism |
5 |
insulin receptor autoantibodies |
5 |
interaction profiling |
5 |
ionization time of flight mass spectrometry |
5 |
ischaemic heart disease |
5 |
isoflurane |
5 |
janus-activated kinase |
5 |
jnk mitogen-activated protein kinases - genetics - metabolism |
5 |
l-arginine |
5 |
left ventricular hypertrophy |
5 |
lipocalins - genetics - physiology |
5 |
lipoprotein lipase |
5 |
liquid chromatography-tan-dem mass spectrometry |
5 |
longevity regulator |
5 |
macrophages - metabolism |
5 |
manikin, intubation tent |
5 |
matrix-assisted laser desorption |
5 |
medical audit |
5 |
mice, obese |
5 |
midazolam |
5 |
mitochondrial dysfunction |
5 |
mitochondrial proteins - genetics - metabolism |
5 |
monitoring, intraoperative - methods |
5 |
morphine - administration & dosage |
5 |
mouse model |
5 |
multinodular goiter |
5 |
muscle contraction - drug effects |
5 |
muscle, smooth, vascular - physiology |
5 |
myocardial hypertrophy and dysfunction |
5 |
na+-k+-atpase |
5 |
nerve tissue proteins - metabolism |
5 |
nervous system development |
5 |
neural crest progenitors |
5 |
neurog2 |
5 |
nf-κb |
5 |
nfκb |
5 |
nitric oxide synthase |
5 |
norepinephrine - pharmacology |
5 |
nrf2 |
5 |
obesity - metabolism - physiopathology |
5 |
obesity - physiopathology |
5 |
oncogene proteins - deficiency - genetics - physiology |
5 |
oxygen - metabolism |
5 |
pain measurement |
5 |
pain, postoperative - drug therapy |
5 |
polyamination |
5 |
porphyrin derivative |
5 |
potassium channels |
5 |
propofol - pharmacology |
5 |
prospective studies |
5 |
prostaglandin |
5 |
prostaglandin e2 |
5 |
prostanoids |
5 |
protein binding |
5 |
protein interaction mapping - methods |
5 |
protein kinase a |
5 |
protein kinase inhibitors - metabolism - pharmacology |
5 |
proteins - metabolism |
5 |
proteomics |
5 |
proto-oncogene proteins c-akt - metabolism |
5 |
rapid sequence intubation |
5 |
rat mesenteric arteries |
5 |
recombinant proteins - genetics - metabolism |
5 |
rna interference |
5 |
ros |
5 |
ruboxistaurin |
5 |
sedation |
5 |
signal transducer and activator of transcription 3 |
5 |
signaling |
5 |
sirolimus |
5 |
sirt3 |
5 |
sirtuin 1 |
5 |
sirtuin 3 |
5 |
sirtuins - genetics - metabolism |
5 |
social deprivation |
5 |
sox10 |
5 |
spatial uncertainty |
5 |
stem cells - drug effects - metabolism - physiology |
5 |
students, medical |
5 |
telomere |
5 |
tomography, x-ray computed |
5 |
total intravenous anesthesia |
5 |
traditional chinese medicine |
5 |
transcription factor ap-1 - genetics - metabolism |
5 |
transcription factor yy1 |
5 |
ttf1 |
5 |
type b insulin resistance |
5 |
acacetin |
4 |
acetylcholine |
4 |
action potentials - drug effects |
4 |
acupuncture analgesia |
4 |
acute pain |
4 |
adipocyte fatty acid binding protein |
4 |
adipokines - metabolism - pharmacology |
4 |
adiponectin - deficiency - hysiology - therapeutic use |
4 |
adiponectin receptor |
4 |
adipor |
4 |
adult population |
4 |
ageing |
4 |
alzheimer's disease |
4 |
amino acid substitution |
4 |
amyloidosis |
4 |
analgesics |
4 |
analgesics - therapeutic use |
4 |
analgesics, opioid - pharmacology |
4 |
analgesics, opioid - therapeutic use |
4 |
analysis of variance |
4 |
anesthesia |
4 |
anesthesia, general |
4 |
anesthesia, obstetrical |
4 |
angiotensin ii |
4 |
animal model |
4 |
antibody drug candidate |
4 |
antioxidants - pharmacology |
4 |
aorta - physiology |
4 |
apocynin |
4 |
apolipoprotein |
4 |
audiovisual aids |
4 |
autoimmunity |
4 |
biological factors - pharmacology |
4 |
biological markers |
4 |
bispectral index (bis) |
4 |
blood loss, surgical - prevention & control |
4 |
blood pressure - drug effects - physiology |
4 |
blood pressure - physiology |
4 |
blood transfusion |
4 |
blood vessels - drug effects - metabolism |
4 |
blotting, western |
4 |
bms309403 |
4 |
brachial plexus |
4 |
brg1 |
4 |
c-jun n-terminal kinase |
4 |
calcium dysfunction |
4 |
cardioprotection |
4 |
cardiovascular diseases - metabolism - prevention and control |
4 |
carotid artery |
4 |
caveolin-3 |
4 |
cgmp |
4 |
chemokines |
4 |
child, preschool |
4 |
children |
4 |
china |
4 |
chronic disease |
4 |
clinical competence |
4 |
clinical outcomes |
4 |
clinical pathway |
4 |
colorectal surgery |
4 |
comprehension |
4 |
conscious sedation - methods |
4 |
coronary vessels - drug effects - metabolism - physiology |
4 |
coronary vessels - drug effects - physiology |
4 |
coronavirus |
4 |
cox-1 |
4 |
creb-h |
4 |
critical pathways - organization and administration |
4 |
cyclic gmp - biosynthesis |
4 |
cyclic gmp - metabolism |
4 |
cyclooxygenase 1 - physiology |
4 |
cyclooxygenase 2 - physiology |
4 |
deamino arginine vasopressin - pharmacology |
4 |
dementia |
4 |
dental surgery |
4 |
desmopressin |
4 |
diabetes mellitus, experimental - drug therapy - metabolism |
4 |
diabetic complication |
4 |
distal radial fracture fixation |
4 |
dogs |
4 |
edcf |
4 |
electric stimulation |
4 |
electroacupuncture |
4 |
endocrinology |
4 |
endothelial cells - drug effects - metabolism |
4 |
endothelial factors |
4 |
endothelium, vascular - physiopathology |
4 |
endothelium-dependent relaxing factors - pharmacology |
4 |
endothelium-derivedcontractingfactor(s) |
4 |
epidermal growth factor receptor transactivation |
4 |
et-1 |
4 |
extracellular matrix |
4 |
fish oil |
4 |
flavones - metabolism - pharmacology |
4 |
fractured neck of femur |
4 |
g protein activation |
4 |
genomics |
4 |
geriatric hip fracture |
4 |
gi proteins |
4 |
gi/o protein |
4 |
glucose transporter type 2 |
4 |
glucose-stimulated insulin secretion |
4 |
gtp-binding protein alpha subunits, gi-go - metabolism |
4 |
guanylate cyclase - antagonists & inhibitors |
4 |
guidelines |
4 |
guinea pigs |
4 |
healthy living |
4 |
hek293 cells |
4 |
hemin |
4 |
hemostasis - drug effects |
4 |
high intensity focused ultrasound |
4 |
high-fat diet |
4 |
high-fat-diet-induced obesity |
4 |
hkv1.5 |
4 |
hot temperature |
4 |
human |
4 |
human neural stem cells |
4 |
hypertension - physiopathology |
4 |
hypnotics and sedatives |
4 |
immune response |
4 |
infraclavicular nerve block |
4 |
infusions, parenteral |
4 |
innate immunity |
4 |
intermittent hypoxia |
4 |
interventional radiology |
4 |
intrathecal morphine |
4 |
intravenous: propofol |
4 |
ion channel gating - drug effects |
4 |
ischaemia/reperfusion injury |
4 |
ischemic preconditioning |
4 |
isoflurane - pharmacology |
4 |
isoflurane postconditioning |
4 |
kv1.5 potassium channel - antagonists and inhibitors - chemistry - genetics |
4 |
laparoscopy |
4 |
large-conductance calcium-activated potassium channels - antagonists & inhibitors |
4 |
length of stay - statistics and numerical data |
4 |
lipids |
4 |
liver tumor |
4 |
local |
4 |
membrane estrogen receptor |
4 |
methods |
4 |
microarray |
4 |
molar, third - surgery |
4 |
morphine |
4 |
motor neurons |
4 |
mouse models |
4 |
multidisciplinary |
4 |
multiple lowdose streptozotocin-induced diabetes |
4 |
muscle, smooth, vascular - drug effects - metabolism - physiology |
4 |
myocardial ischaemia/reperfusion injury |
4 |
myocardial reperfusion injury |
4 |
myocardium - pathology |
4 |
narcotic antagonists - pharmacology |
4 |
natriuretic peptides - pharmacology - physiology |
4 |
nephrology |
4 |
neutralizing monoclonal antibody 6h2 |
4 |
nf-kappa b - metabolism |
4 |
nitric oxide - metabolism - pharmacology - physiology |
4 |
nitric oxide donors - pharmacology |
4 |
nitric oxide synthase type iii - metabolism |
4 |
no |
4 |
open channel blockade |
4 |
osmolar concentration |
4 |
oxadiazoles - pharmacology |
4 |
oxazines - pharmacology |
4 |
oxidation-reduction |
4 |
oxygen-derived free radicals |
4 |
paediatric |
4 |
pain, postoperative - diagnosis - prevention and control |
4 |
patient care team - organization and administration |
4 |
patient simulation |
4 |
peptides - pharmacology |
4 |
pertussis toxin |
4 |
pethidine |
4 |
pharmacology |
4 |
phosphorylation |
4 |
pig coronary artery |
4 |
pilot projects |
4 |
pkc-ε |
4 |
pluripotent stem cells |
4 |
polyunsaturated fatty acids |
4 |
porcine coronary artery angioplasty |
4 |
postoperative analgesia |
4 |
postoperative opioid consumption |
4 |
potassium channel blockers - metabolism - pharmacology |
4 |
ppar gamma - agonists - metabolism |
4 |
pregnancy |
4 |
preoperative assessment |
4 |
prostacyclin synthase |
4 |
public housing |
4 |
quality of life |
4 |
rabbits |
4 |
rap1 |
4 |
rate-dependent blockade |
4 |
receptors, adiponectin - metabolism |
4 |
regeneration |
4 |
regional anaesthesia |
4 |
regional anesthesia |
4 |
repeated non-invasive limb ischemic preconditioning |
4 |
reproducibility of results |
4 |
respiratory infectious disease |
4 |
retrospective studies |
4 |
risk factors |
4 |
scoliosis - surgery |
4 |
serotonin |
4 |
shock - metabolism - physiopathology |
4 |
signal transduction - drug effects |
4 |
smooth muscle cell |
4 |
socioeconomic factors |
4 |
sox9 |
4 |
spinal cord |
4 |
spinal cord injury |
4 |
spontaneously hypertensive rats |
4 |
stat3 |
4 |
statins |
4 |
stress |
4 |
superoxide dismutase - metabolism |
4 |
surgical procedures, operative |
4 |
surgical wound infection - prevention and control |
4 |
surveys and questionnaires |
4 |
swine |
4 |
teaching - methods |
4 |
thermal ablation |
4 |
thiazolidinediones - therapeutic use |
4 |
tonic blockade |
4 |
tooth extraction - adverse effects |
4 |
total intravenous anaesthesia (tiva) |
4 |
tp receptor |
4 |
transfection |
4 |
type 1diabetes |
4 |
vascular |
4 |
vascular diseases - physiopathology - prevention & control |
4 |
vascular homeostasis |
4 |
vasculature |
4 |
vasoconstriction/dilation |
4 |
vasodilation |
4 |
vasodilation - drug effects - physiology |
4 |
young adult |
4 |
1-(5-isoquinolinesulfonyl)-2-methylpiperazine - analogs & derivatives - chemistry - pharmacology |
3 |
3′-5′-cyclic adenosine monophosphate (cyclic amp) |
3 |
8-bromo cyclic adenosine monophosphate - pharmacology |
3 |
acetylation |
3 |
acute disease |
3 |
acute myocardial infarction |
3 |
adenylate cyclase - metabolism |
3 |
administration, oral |
3 |
adrenergic alpha-2 receptor agonists - pharmacology |
3 |
adrenergic beta-antagonists - pharmacology |
3 |
age distribution |
3 |
aged, 80 and over |
3 |
algorithms |
3 |
allopurinol |
3 |
amides - chemistry - pharmacology |
3 |
amp-activated protein kinase |
3 |
amygdala |
3 |
anaesthetics i.v., propofol |
3 |
anaesthetics volatile, sevoflurane |
3 |
analgesia - adverse effects |
3 |
analgesia intra-articular |
3 |
analgesic efficacy |
3 |
analgesics non-opioid ketorolac |
3 |
analgesics, opioid |
3 |
analgesics, opioid - administration & dosage |
3 |
analgesics, opioid - administration and dosage |
3 |
analgesics, opioid - adverse effects |
3 |
analgesics, opioid - metabolism - therapeutic use |
3 |
anesthesia recovery period |
3 |
anesthesia, local |
3 |
anesthesia, spinal |
3 |
anesthetics |
3 |
aneurysms |
3 |
ang ii type 1 receptors |
3 |
anoxia - metabolism - physiopathology |
3 |
anti-arrhythmia agents - pharmacology |
3 |
anti-inflammation |
3 |
anti-inflammatory agents - pharmacology - therapeutic use |
3 |
anti-inflammatory agents, non-steroidal - therapeutic use |
3 |
antifibrinolytic agents - therapeutic use |
3 |
antihypertensive agents - chemistry - pharmacology |
3 |
aorta - drug effects |
3 |
aorta - metabolism |
3 |
aorta, thoracic - drug effects - enzymology - physiopathology |
3 |
apoptosis - drug effects |
3 |
arginine - pharmacology |
3 |
arrhythmia |
3 |
arteries - metabolism - physiology |
3 |
arthroplasty, replacement, knee |
3 |
astrocyte |
3 |
atherosclerosis - enzymology - pathology |
3 |
atrial fibrillation - drug therapy - prevention & control |
3 |
atrial function - drug effects |
3 |
atropine - pharmacology |
3 |
auditing |
3 |
autophagy |
3 |
basement membrane |
3 |
berberine - pharmacology - therapeutic use |
3 |
biological effects |
3 |
blended learning |
3 |
blood vessel remodeling |
3 |
bone marrow |
3 |
bone morphogenetic protein 4 - antagonists & inhibitors - metabolism |
3 |
bone morphogenetic protein receptors, type i - metabolism |
3 |
bone morphogenic protein 4 |
3 |
bupivacaine |
3 |
burden of disease |
3 |
calcimycin - pharmacology |
3 |
calcium - metabolism |
3 |
calcium channel blockers - pharmacology |
3 |
calcium channels - metabolism |
3 |
calcium sensitization |
3 |
camp-dependent protein kinase |
3 |
cancer chemotherapy |
3 |
cardiac biomarkers |
3 |
cardiac complications |
3 |
cardiac output |
3 |
cardiac protection |
3 |
cardiotonic agents |
3 |
cardiotonic agents - pharmacology |
3 |
cardiovascular agents - administration & dosage |
3 |
cardiovascular diseases - drug therapy - physiopathology |
3 |
carrier proteins - metabolism - pharmacology |
3 |
catalase - drug effects - metabolism |
3 |
caveolae |
3 |
cell adhesion |
3 |
cell aging - physiology |
3 |
cell isolation |
3 |
cell proliferation - drug effects |
3 |
cell survival - drug effects |
3 |
cesarean section |
3 |
cgmp-dependent protein kinase |
3 |
cgmp-dependent protein kinase, porcine coronary artery |
3 |
chemobrain |
3 |
chloral hydrate |
3 |
chromatography, high pressure liquid |
3 |
chronic |
3 |
chronic post-ischaemic pain |
3 |
chronic post-ischemia pain |
3 |
chronic regional pain syndrome |
3 |
circulating tumour cells |
3 |
clinical effectiveness |
3 |
clonidine |
3 |
cognition dysfunction |
3 |
cognitive dysfunction |
3 |
colorectal |
3 |
comorbidity |
3 |
continuous femoral nerve block |
3 |
contrast media |
3 |
controlled study |
3 |
coronary artery bypass graft surgery |
3 |
coronary artery, porcine |
3 |
coronary vessels - drug effects - enzymology - physiology |
3 |
coronary vessels - drug effects - metabolism - physiopathology |
3 |
coronary vessels - physiology |
3 |
cross-over studies |
3 |
crossover procedure |
3 |
curriculum |
3 |
cxcl12 |
3 |
cxcl12/cxcr4 axis |
3 |
cxcr4 |
3 |
cyclic amp - physiology |
3 |
cyclic amp-dependent protein kinases - physiology |
3 |
cyclic gmp-dependent protein kinases - chemistry - physiology |
3 |
cyclic gmp-dependent protein kinases - metabolism |
3 |
cyclic guanosine monophosphate |
3 |
cyclic nucleotides |
3 |
cyclin-dependent kinase 5 |
3 |
cyclin-dependent kinase 5 - antagonists and inhibitors - physiology |
3 |
cyclooxygenase 2 - genetics - metabolism |
3 |
cyclooxygenase 2 - metabolism |
3 |
cyclooxygenase inhibitors - administration & dosage - blood - therapeutic use |
3 |
cyclooxygenase-2 |
3 |
cyclooxygenases |
3 |
cytokines |
3 |
cytokines and epigenetics |
3 |
damage |
3 |
data collection |
3 |
deamino arginine vasopressin - therapeutic use |
3 |
dexmedetomidine - administration and dosage - adverse effects - pharmacology |
3 |
dexmedetomidine - pharmacology |
3 |
diabetes mellitus, experimental - chemically induced - metabolism - physiopathology |
3 |
difficult airway |
3 |
dihydropyridine |
3 |
dihydropyridines - pharmacology |
3 |
disulfide bonds |
3 |
double blind procedure |
3 |
drug administration schedule |
3 |
drugs |
3 |
e-learning |
3 |
eicosanoids |
3 |
endothelial cells - drug effects - enzymology |
3 |
endothelial cells - drug effects - physiology |
3 |
endothelial cells - metabolism |
3 |
endothelin type a receptor |
3 |
endothelin-1 - genetics - metabolism |
3 |
endothelium, vascular - drug effects - enzymology - physiology |
3 |
endothelium, vascular - drug effects - metabolism |
3 |
endothelium, vascular - enzymology |
3 |
endothelium, vascular - enzymology - metabolism - pathology |
3 |
endothelium-dependent contraction |
3 |
endothelium-derived hyperpolarization |
3 |
endotoxemia |
3 |
endovascular procedures |
3 |
enhanced recovery after surgery |
3 |
enzyme activation |
3 |
enzyme activation - drug effects |
3 |
ep4 receptor |
3 |
equilibrative nucleoside transporter 1 - antagonists & inhibitors - genetics - metabolism |
3 |
equilibrative-nucleoside transporter 2 - antagonists & inhibitors - genetics - metabolism |
3 |
erythropoiesis |
3 |
erythropoietin |
3 |
estradiol - pharmacology |
3 |
estrogen |
3 |
estrogen receptor beta |
3 |
evoked potentials, somatosensory - drug effects |
3 |
experimental mouse model |
3 |
extremely hot weather event |
3 |
fat |
3 |
femoral artery - drug effects - metabolism - physiopathology |
3 |
femoral neck fracture |
3 |
femoral nerve |
3 |
fentanyl |
3 |
fgfr1 |
3 |
flavones - pharmacology - therapeutic use |
3 |
forkhead box protein o1 |
3 |
formaldehyde |
3 |
fractured hip |
3 |
free radical scavengers |
3 |
g-proteins |
3 |
gap junction |
3 |
gerotarget |
3 |
glial–glial crosstalk |
3 |
global |
3 |
glucocorticoid receptor |
3 |
guanylate cyclase - chemistry - physiology |
3 |
gut microbiota |
3 |
haemoglobin |
3 |
health surveys |
3 |
healthcare utilisation |
3 |
heart infarction size |
3 |
heart muscle ischemia |
3 |
heart-type fatty acid binding protein |
3 |
hemodilution |
3 |
hemodynamics |
3 |
hepatic ischaemiareperfusion injury |
3 |
hip fracture repair |
3 |
hydrogen peroxide |
3 |
hydrogen peroxide - antagonists & inhibitors - pharmacology |
3 |
hydrogen peroxide - metabolism |
3 |
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use |
3 |
hyperglycemia - drug therapy - metabolism |
3 |
hyperlipidemia |
3 |
hypertension - drug therapy - enzymology - physiopathology |
3 |
hypertension - drug therapy - physiopathology |
3 |
hypertension - genetics - metabolism |
3 |
hypertension, renal - metabolism |
3 |
hypotension |
3 |
hypotension - chemically induced |
3 |
hypotension - etiology |
3 |
hypothermia - blood |
3 |
ibuprofen |
3 |
il-6 |
3 |
in ovo electroporation |
3 |
inflammation - drug therapy - physiopathology |
3 |
infusions, intravenous |
3 |
injections, spinal |
3 |
intermediate-conductance calcium-activated potassium channels |
3 |
intubation, intratracheal |
3 |
ion channels |
3 |
ischaemia reperfusion injury |
3 |
ischemia |
3 |
ischemic postconditioning - methods |
3 |
ischemic preconditioning, myocardial |
3 |
ischemic preconditioning, myocardial - methods |
3 |
isoflurane - therapeutic use |
3 |
isometric contraction - drug effects |
3 |
isoproterenol - pharmacology |
3 |
isoxazoles - administration & dosage - blood - therapeutic use |
3 |
issue 148 |
3 |
jnk |
3 |
kaempferol |
3 |
kaempferols - pharmacology |
3 |
ketorolac - administration & dosage - blood - therapeutic use |
3 |
klb |
3 |
large-conductance calcium-activated potassium channels - agonists |
3 |
laryngeal mask airway |
3 |
liver |
3 |
liver - blood supply - drug effects - metabolism |
3 |
liver diseases - metabolism - prevention and control |
3 |
liver transplantation |
3 |
map kinase signaling system - physiology |
3 |
matrix metalloproteinase-2 |
3 |
maxilla - surgery |
3 |
medicine, chinese traditional |
3 |
melanoma |
3 |
meperidine |
3 |
mesenteric arteries - drug effects |
3 |
mesenteric artery, superior - drug effects - enzymology |
3 |
metabolic regulation |
3 |
metastasis prediction |
3 |
metastatic |
3 |
methodology |
3 |
microcirculation |
3 |
microscopy, confocal - methods |
3 |
minimally invasive surgery |
3 |
mitochondria |
3 |
models, biological |
3 |
modernization |
3 |
monitoring |
3 |
monitoring, somatosensory evoked potential |
3 |
morphine - administration and dosage |
3 |
morphine - administration and dosage - metabolism |
3 |
morphine - adverse effects |
3 |
morphine - pharmacology |
3 |
muscle contraction - drug effects - physiology |
3 |
myocardial contraction - drug effects |
3 |
myocardial infarction |
3 |
myocardial infarction - metabolism - pathology - prevention & control |
3 |
myocardial injury |
3 |
myocardial ischemia |
3 |
myocardial ischemia-reperfusion |
3 |
myocardial reperfusion injury - metabolism - pathology - prevention & control |
3 |
myocardial reperfusion injury - prevention and control |
3 |
myocytes, cardiac |
3 |
n-methyl-d-aspartate receptors |
3 |
nausea - chemically induced |
3 |
nedd9 |
3 |
nerve block - adverse effects |
3 |
nerve block - methods |
3 |
neuromodulator |
3 |
neuropathic |
3 |
nitrative stress |
3 |
nitric oxide synthase - drug effects - metabolism |
3 |
nitrosative stress |
3 |
nociceptors - drug effects |
3 |
non-cancer pain |
3 |
non-genomic effects |
3 |
noncardiac surgery |
3 |
nongenomic |
3 |
notoginsenoside ft1 |
3 |
nuclear factor of activated t-cells 5 |
3 |
nuclear factor-kappa b |
3 |
nucleoside |
3 |
ondansetron - therapeutic use |
3 |
operative |
3 |
opioid requirements |
3 |
opioid rotation |
3 |
opioid therapy |
3 |
organ culture techniques |
3 |
osteotomy - adverse effects - methods |
3 |
outcome |
3 |
oxidants - pharmacology |
3 |
oxidative stress - drug effects |
3 |
oxidative stress - physiology |
3 |
oxygen - blood |
3 |
oxygen consumption - physiology |
3 |
p21 |
3 |
p25 |
3 |
p38 mitogen-activated protein kinases - metabolism |
3 |
pain clinics - standards |
3 |
pain measurement - methods |
3 |
pain, postoperative - prevention and control |
3 |
pain: postoperative |
3 |
painpaired box gene 2 |
3 |
panax notoginseng |
3 |
parecoxib |
3 |
pathological pain |
3 |
pathophysiological changes |
3 |
patient-controlled |
3 |
perioperative care |
3 |
peroxisome proliferator-activated receptor agonist |
3 |
persistent opioid use |
3 |
pharmacogenetics |
3 |
pi3k |
3 |
piperidines - therapeutic use |
3 |
pkg |
3 |
pneumonia |
3 |
pneumothorax |
3 |
polymorphisms |
3 |
populations/contexts |
3 |
post-ischemic myocardial injury |
3 |
postconditioning |
3 |
postoperative care |
3 |
postoperative cognitive dysfunction |
3 |
postoperative complications |
3 |
postoperative complications - prevention & control |
3 |
postoperative nausea and vomiting |
3 |
postoperative outcomes |
3 |
postoperative period |
3 |
potassium - metabolism |
3 |
pparγ |
3 |
pre-emptive |
3 |
preconditioning |
3 |
premedication - methods |
3 |
preoperative care |
3 |
pressure |
3 |
pro-inflammatory cytokines |
3 |
proinflammatory cytokines |
3 |
propanolamines - pharmacology |
3 |
propofol - therapeutic use |
3 |
prostaglandin e receptor |
3 |
protein kinase c - physiology |
3 |
protein kinases |
3 |
pten |
3 |
puerarin |
3 |
pyridines - chemistry - pharmacology |
3 |
quaternary ammonium compounds - pharmacology |
3 |
questionnaires |
3 |
rac1 |
3 |
radix puerariae |
3 |
rats, wistar |
3 |
reaction time - drug effects |
3 |
receptor-mediated contraction |
3 |
receptors, cytoplasmic and nuclear - chemistry - physiology |
3 |
receptors, opioid - agonists - metabolism |
3 |
receptors, opioid - drug effects - physiology |
3 |
receptors, opioid, delta - agonists |
3 |
receptors, opioid, kappa - agonists |
3 |
receptors, opioid, mu - agonists |
3 |
receptors, prostaglandin e - physiology |
3 |